Milestone Pharmaceuticals (MIST) Total Liabilities (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Total Liabilities for 9 consecutive years, with $163.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 150.77% year-over-year to $163.4 million; the trailing twelve-month figure through Jun 2026 stood at $163.4 million (up 150.77% YoY), and the FY2025 full-year result was $71.8 million, up 15.14% from the prior year.
• Total Liabilities advanced to $163.4 million in Q2 2026 per MIST's latest filing, from $157.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $163.4 million in Q2 2026 and bottomed at $4.6 million in Q2 2022.
• Historically, Total Liabilities has averaged $60.3 million across 5 years, with a median of $58.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities slipped 21.83% in 2022, then surged 1120.06% in 2023.
• Over 5 years, Total Liabilities stood at $8.1 million in 2022, then soared by 618.56% to $58.5 million in 2023, then grew by 6.67% to $62.4 million in 2024, then rose by 15.14% to $71.8 million in 2025, then jumped by 127.61% to $163.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $163.4 million, $157.7 million, and $71.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.